Beyond Air (XAIR)

Executive Summary

Beyond Air is a clinical-stage medical device and biopharmaceutical company pioneering inhaled nitric oxide (iNO) therapy through its proprietary LungFit platform. LungFit generates nitric oxide on-demand from ambient air, eliminating the need for cumbersome gas cylinders and enabling scalable, cost-effective treatment across multiple settings. The company is initially targeting neonatal hypoxic respiratory failure, a condition affecting thousands of newborns annually, where iNO is standard of care but supply chain limitations persist. Beyond Air’s platform offers a robust alternative with potential for broader adoption in hospital and home environments. Beyond Air's pipeline extends into severe viral pneumonia and chronic lung infections, addressing significant unmet needs in infectious disease. The company is advancing clinical trials to validate the efficacy of iNO as an antimicrobial and anti-inflammatory agent. Key near-term milestones include potential FDA clearance for expanded indications and pivotal data readouts. With a strong intellectual property portfolio and partnerships in development, Beyond Air is positioned to disrupt the iNO market. However, regulatory and commercialization risks remain typical for a clinical-stage company.

Upcoming Catalysts (preview)

• Q4 2026FDA clearance of LungFit for neonatal hypoxic respiratory failure70% success
• H1 2027Topline results from Phase 3 trial of iNO in severe viral pneumonia50% success
• Q2 2026Strategic partnership for LungFit in chronic lung infections40% success